New cancer drug combo enters first human tests

NCT ID NCT05789069

Summary

This is an early-stage study to find a safe dose of a new immunotherapy drug called HFB200603. It will be tested alone and in combination with an existing drug, tislelizumab, in 83 adults with advanced solid tumors like lung, kidney, or skin cancer. The main goal is to check for side effects and determine the best dose for future studies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centro Ricerche Cliniche di Verona s.r.l.

    Verona, 37134, Italy

  • Clinica Universidad de Navarra - Madrid

    Madrid, 28027, Spain

  • Clinica Universidad de Navarra - Pamplona

    Pamplona, 31008, Spain

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

    Naples, 80131, Italy

  • New Experimental Therapeutics of Virginia - NEXT Oncology

    Fairfax, Virginia, 22031, United States

  • South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC

    Madrid, 28050, Spain

  • South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, 00168, Italy

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

Conditions

Explore the condition pages connected to this study.